The revolutionary molecular chaperone amplification technology of this company is a breakthrough for the Biotechnology & Drugs Industry. It brings the regeneration of nerve fibers from the science fiction of the past to the realm of reality. This is no matter for academic appreciation alone, because one of the worst side-effects of poorly managed diabetes is the irreversible effects of decay it has on the nervous system.
Diabetes is one of the most rapidly growing diseases of modern societies, with special vulnerabilities for certain ethnic groups. This Los Angeles, CA based company has a May 2008 market capitalization of less than $65 million, but it has a historic potential impact on the entire Healthcare Sector.
The company’s platform technology is flexible, and can be theoretically used for a variety of drugs. Early results from clinical trials have established both efficacy and safety. The company has a rich pipeline of exciting developmental projects. It is likely to have a lasting effect on taking medicine to new frontiers.
The company has a separate technology related to ribonucleic acid interference. This has major potential applications in treating blocked and diseased blood vessels-something that has only been partially managed by invasive surgery until now. The company’s technology has the potential for delivery in oral formulation. The management has shown great strategic acumen in transferring this entire line of new drug development to a separate company.
It is extraordinary that stock of such an exceptional enterprise was available at the end of the second week of May 2008 for just 71 cents. It is an investment opportunity needed to be watched.
Let us hear your thoughts below: